MARKET

GMAB

GMAB

Genmab
NASDAQ
30.90
-0.07
-0.23%
After Hours: 30.80 -0.1 -0.32% 19:56 02/06 EST
OPEN
30.94
PREV CLOSE
30.97
HIGH
31.31
LOW
30.75
VOLUME
1.76M
TURNOVER
--
52 WEEK HIGH
35.43
52 WEEK LOW
17.24
MARKET CAP
19.02B
P/E (TTM)
12.76
1D
5D
1M
3M
1Y
5Y
1D
Genmab Updates Articles of Association to Expand Capital-Raising and Incentive Flexibility
TipRanks · 3d ago
Weekly Report: what happened at GMAB last week (0126-0130)?
Weekly Report · 5d ago
Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance
Seeking Alpha · 01/30 03:30
Genmab Grants New RSUs and Warrants to Employees to Strengthen Long-Term Incentives
TipRanks · 01/29 18:58
Genmab Grants Restricted Stock Units and Warrants to Employees
Reuters · 01/29 17:48
The Analyst Verdict: Genmab In The Eyes Of 4 Experts
Benzinga · 01/28 14:00
Genmab Price Target Maintained With a $39.00/Share by HC Wainwright & Co.
Dow Jones · 01/28 13:53
HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $39 Price Target
Benzinga · 01/28 13:43
More
About GMAB
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Webull offers Genmab A/S - ADR stock information, including NASDAQ: GMAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GMAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GMAB stock methods without spending real money on the virtual paper trading platform.